2009.05.29 – Clinical and hematological presentation of children and adolescents with polycythemia vera

Pages

• Home
• Blog
• Donate
• Pennsylvania Drinking Water- Is Your Drinking Water Safe?
• About Us
• Education
• Homeowners
• Polycythemia vera
  • *P vera Media Articles
  • P. vera Links
  • P. vera "Science"
    • 2006.11.06 - POLYCYTHEMIA PROTOCOL: THE INVESTIGATION OF POLYCYTHEMIA VERA INCIDENCE IN THE TAMAQUA AREA OF PENNSYLVANIA
    • 2006.11.XX - ON THE TRAIL OF A POINT MUTATION THE DISCOVERY OF A BLOOD-CANCER GENE RAISES TANTALIZING QUESTIONS
    • 2006.12.10 - GENE MUTATION PREDICTS OUTCOME IN BLOOD DISORDER [ABSTRACT #5]
    • 2007.11.16 - ATSDR PV Abstract
    • 2001.12.xx - Cancer Mail from the National Cancer Institute
    • 2006.03.07 - Fourth Generation P. vera
    • 2006.04.07 - Mutation In Blood Stem Cells
    • 2007.04.21 - Options limited for blood illness (PV)
    • 2007.08.24 - POINTING THE ATSDR IN THE RIGHT DIRECTION
    • 2007.10.12 - Incyte's Novel JAK Inhibitor, INCB18424
    • 2007.11.12 - JAK2-V617F or JAK2 exon 12 mutations
    • 2007.11.20 - First Quantitative JAK2 V617F Mutation Kit
    • 2007.11.23 - Merck_Manual
    • 2007.12.05 - Top Scientists to Receive Prestigious Awards
    • 2007.12.06 - Initiation of Clinical Trial of JAK2 Inhibitor
    • 2007.12.07 - Researcher Discovers What Fuels Certain Cancer Mutation
    • 2007.12.10 - A Novel Selective Inhibitor of JAK2
    • 2007.12.10 - OHSU Cancer Institute researcher discovers what fuels certain cancer mutation
    • 2007.12.11 - Understanding Chronic Myeloid Leukemia
    • 2007.12.12 - New Cancer Discovery, Hormone to Blame
    • 2007.12.12 - Phase I data for myelofibrosis drug
    • 2008.01.08 - Incyte to Report Positive Clinical Results from JAK Inhibitor
    • 2008.01.08 - Results of Polycythemia Vera Investigation
    • 2008.01.14 - Dr. Mehta-A new blood test-Do we know JAK?
    • 2008.01.22 - JAK2V617F mutation screening in WHO 2008 criteria
    • 2008.02.29 - myeloproliferative disease support group
    • 2008.03.07 - New Genetic Test Detects PV
    • 2008.03.17 - JAK2 Clinical Candidate
    • 2008.04.07 - Drug Targets Three Kinds of Leukemia
    • 2008.04.07 - New Therapy for Rare Blood Disorder
    • 2008.04.07 - Treatment reverses blood disorder in mice, study finds
    • 2008.04.15 - Drug Successfully Treats Chronic Blood Cancer In Mice
    • 2008.08.xx - Weird- Cancer Cluster in Northeastern PA
    • 2008.09.22 - Too much iron brings increased health risks
    • 2008.10.26 - JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement
    • 2008.12.08 - Competitor Analysis for Janus Kinase (JAK) Inhibitors
    • 2008.12.09 - Promising new drug blocks mutation in bone marrow cancers
    • 2009.01.08 - PV_ therapy-resistant cancers
    • 2009.01.30 - Treatment of Hematological Malignancies
    • 2009.03.15 - germline JAK2 SNP is associated with
    • 2009.03.xx - Federal Agency Fails to Protect People
    • 2009.05.04 - JAK2 Molecular Diagnostic Assays
    • 2009.05.14 - Father Sues Utility
    • 2009.05.22 - Is there a cancer cluster in Love Canal
    • 2008.10.30 - link between coal combustion waste, rare cancer cluster
    • 2009.03.17 - Are waste-coal power plants making us sick?
    • 2009.05.27 - Recombinant Human Erythropoietin Injection
    • 2009.05.27 - Astex reports positive data from its Phase I study
    • 2009.05.28 - A Common Genetic Mechanism in Malignant Bone Marrow Diseases
    • 2009.05.28 - Mutation in TET2 in Myeloid Cancers
    • 2009.05.28 - Search_Results_NEJM_JAK2
    • 2009.05.28 - Incyte Provides Update on Special Protocol Assessment for INCB18424
    • 2009.05.29 - Clinical and hematological presentation of children and adolescents with polycythemia vera
    • 2009.05.29 - FDA, Clinical Trial Updates- JNJ, INCY, MEDX, CYTX, AGN, PPHM
    • 2009.05.29 - TET2 defects present early in myeloid cancers
    • 2009.05.28 - Candidate Tumor Suppressor Gene Implicated in Myeloid Cancers
    • 2009.01.06 - The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis
    • 2009.06.01 - Incyte Provides Update On Special Protocol Assessment For INCB18424 As A New Treatment For Myelofibrosis
    • 2009.05.29 -Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
    • 2009.06.04 - Gene and microRNA analysis of neutrophils from patients with polycythemia vera
    • 2009.06.07 - An Insight On Incyte Corp
    • 2009.06.08 - Mutation in TET2 in Myeloid Cancers
    • 2009.06.19 - Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
    • 2009.06.19 - Cephalon Cancer Drug Shows No Increase In Survival Rate
    • 2009.06.22 - Cytopia Lodges IND for JAK2 Inhibitor CYT387
    • 2009.06.18 - Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
    • 2009.06.29 - Analysis of the Ten-Eleven Translocation (TET)2 gene in familial myeloproliferative neoplasms
    • 2009.03.05 - Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
    • 2009.03.05 - TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    • 2009.06.14 - Analysis of the Ten-Eleven Translocation (TET)2 gene in familial myeloproliferative neoplasms
    • 2009.07.02 - Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
    • 2009.07.21 - Assessment for INCB18424
    • 2009.07.24 - JAK2 V617F mutation is associated with 5q- syndrome in Chinese
    • 2009.07.24 - JAK2 V617F mutation in myeloid neoplasms with 3q21 and 3q26 abnormalities in Chinese patients
    • 2008.7.20 - JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN)
    • 2009.05.29 - JAK2V617F-Positive Latent Essential Thrombocythemia and Splanchnic Vein Thrombosis
    • 2009.05.31 - Acquired mutations in TET2 are common in myelodysplastic syndromes.
    • 2009.07.04 - Acquired mutations in TET2 are common in myelodysplastic syndromes
    • 2009.07.28 - New drug for children with high-risk leukemia
    • 2009.07.29 - New drug may help treat childhood leukemia
    • 2009.07.29 - Sheba's Dr. Shai Izraeli discovers novel alternative to chemotherapy for children with leukemia
    • 2009.07.30 - Incyte Provides Update on Drug Development Programs
    • 2009.07.31 -MYELOPROLIFERATIVE DISORDERS – BIOLOGY AND MANAGEMENT
    • 2009.08.01 - Drug Alternative Childhood Leukemia Chemo Developed
    • 2009.08.05 - Onyx Pharmaceuticals - ONX 0803 selective JAK2 inhibitor
    • 2009.08.07 - TET2 mutations in myelodysplasia and myeloid malignancies
    • 2009.08.10 - Incyte Presents Investors with Unique Dilemmas
    • 2009.08.11 - Chronic Myelomonocytic Leukemia with der(9)t(1;9)(q11;q34) as a Sole Abnormality
    • 2009.08.11 - New drug hope for children with leukemia
    • 2009.08.13 - TET2 Mutation Is an Independent Favorable Prognostic Factor in Myelodysplastic Syndromes (MDS)
    • 2009.08.14 - Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cells.
    • 2009.08.16 - Discovery of genetic link to blood cancers
    • 2009.08.20 - Gene Mutation Predicts Outcome In Blood Disorder
    • 2009.08.20 - Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome
    • 2009.08.22 - Pomalidomide Active for Treatment of Anemia of Myelofibrosis
    • 2009.08.25 - JAK2 inhibitor CYT387
    • 2009.08.25 - urbaneangel - POLYCYTHEMIA VERA
    • 2009.08.31 - Genetic Link Between Leukemia And Down’s Syndrome
    • 2009.09.03 - Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials
    • 2009.09.03 - TargeGen Announces Initiation Of Clinical Trial Of JAK2 Inhibitor TG101348 In Myeloproliferative Disease Patients
    • 2009.09.01 - Loss-of-Function TET2 Mutations- Adding Fire to Hematologic Malignancies?
    • 2009.09.04 - The Activation of the JAK2/STAT5 Pathway Is Commonly Involved in Signaling through the Human IL-5 Receptor
    • 2009.09.10 -Mutation in TET2 in Myeloid Cancers
    • 2009.09.10 -Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations
    • 2009.09.11 -Angiotensin II activates JAK2/STAT3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes
    • 2009.09.21 - Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis
    • 2009.09.22 - Incyte says psoriasis drug meets main goal, shares up
    • 2009.09.23 - JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN)
    • 2009.09.23 - How do JAK2-inhibitors work in myelofibrosis- An alternative hypothesis
    • 2009.09.19 - A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.
    • 2009.09.27 - Scientists find broken ‘switch’ link to leukemia
    • 2009.09.28 - New hope in fight against blood cancer
    • 2009.09.28 - Scientists discover new route to leukaemia
    • 2009.09.27 - JAK2 phosphorylates histone H3Y41 and excludes HP1 from chromatin
    • 2009.09.28 - Scientists uncover 'genetic switch' that can trigger leukaemia
    • 2009.09.30 - Splenectomy Normalizes Hematocrit in Murine Polycythemia Vera
    • 2009.09.19 - How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis
    • 2009.09.30 - A broken genetic “switch” has been discovered that can trigger leukaemia.
    • 2009.10.01 - In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients- a new disease paradigm
    • 2009.10.01 - Regulation of JAK2 by miR-135a- prognostic impact in classic Hodgkin lymphoma
    • 2009.10.02 - Cancer Research UK scientists identify a nuclear role for JAK2 in the phosphorylation of H3Y41
    • 2009.10.08 - JAK2 phosphorylates histone H3Y41 and excludes HP1 from chromatin
    • 2009.10.08 - JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.
    • 2009.10.09 - Cytopia achieves grant of further patent for JAK2 program
    • 2008.09.21 - Genetic Link Between Leukemia And Down's Syndrome
    • 2009.10.06 - YM BioSciences inks deal to acquire Cytopia
    • 2009.10.14 - Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells.
    • 2009.10.18 - New Chromosomal Abnormality Identified in Leukemia Associated with Down Syndrome
    • 2009.10.22 - TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients
• Contact Us
• Site Map
• Home